10 November 2017Americas

LSIPR 50 2017: Carl Gordon—Realising great ideas

One of the challenges facing healthcare venture capital firms is the pressure concerning drug pricing.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

Teva fights for re-listing of inhaler patents at US appeals court

White & Case hires experienced litigator from A&O Shearman

President Trump 2.0: Five major areas to watch

China’s new policies on foreign investment in healthcare and biotech

Startup CFO’s betrayal is a lesson in preparing for the worst

Sandoz lands reduced antitrust award of $70m

New president’s to-do list: Patent bills, non-competes, USPTO director?

Sanofi subsidiary fends off $450m trade secrets case

LSIPR 50 2017: Carl Gordon—Realising great ideas

Editor's picks

Editor's picks

More features